Contact
searchSearch
HMP Global
Login

Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Mayur Narkhede, MD
Videos
Real-World Treatment Patterns and Outcomes Among Patients With Mantle Cell Lymphoma
07/21/2022
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed...
07/21/2022
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma
06/15/2022
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates...
06/15/2022
Journal of Clinical Pathways
Bijal Shah, MD
Videos
Real-World Treatment Patterns of Bruton Tyrosine Kinase Inhibitors Among Patients With Mantle Cell Lymphoma
06/14/2022
Bijal Shah, MD, discusses his study which assessed patient characteristics, treatment patterns and associated outcomes in real-world BTKi-treated patients with MCL.
Bijal Shah, MD, discusses his study which assessed patient characteristics, treatment patterns and associated outcomes in real-world BTKi-treated patients with MCL.
Bijal Shah, MD, discusses his...
06/14/2022
Journal of Clinical Pathways
Amer Beitinjaneh, MD, MPH, MSc, Sylvester Comprehensive Cancer Institute, University of Miami Miller School of Medicine
Interview
Real-World Experience With Brexucabtagene Autoleucel for MCL in the United States
03/21/2022
Amer Beitinjaneh, MD, MPH, MSc, discusses results from a study evaluating the safety and efficacy of brexucabtagene autoleucel in standard of care practice for patients with MCL among centers in the US Lymphoma CAR-T Consortium.
Amer Beitinjaneh, MD, MPH, MSc, discusses results from a study evaluating the safety and efficacy of brexucabtagene autoleucel in standard of care practice for patients with MCL among centers in the US Lymphoma CAR-T Consortium.
Amer Beitinjaneh, MD, MPH, MSc,...
03/21/2022
Journal of Clinical Pathways
Peter Martin, MD, Weill Cornell Medicine
Videos
Real-World Treatment Patterns and Outcomes Among Patients With MCL
08/20/2021
Peter Martin, MD, real-world treatment patterns and outcomes among 3455 patients with previously untreated MCL in the United States.
Peter Martin, MD, real-world treatment patterns and outcomes among 3455 patients with previously untreated MCL in the United States.
Peter Martin, MD, real-world...
08/20/2021
Journal of Clinical Pathways
Videos
Bendamustine Plus Rituximab Safe, Effective for Treating MCL in Real-World Setting
07/15/2021
Rouslan Kotchetkov, MD, PhD, discusses results from a retrospective review exploring the efficacy and safety of bendamustine plus rituximab for the treatment of MCL in the real-world setting.
Rouslan Kotchetkov, MD, PhD, discusses results from a retrospective review exploring the efficacy and safety of bendamustine plus rituximab for the treatment of MCL in the real-world setting.
Rouslan Kotchetkov, MD, PhD,...
07/15/2021
Journal of Clinical Pathways
Interview
Ibrutinib Combined With Venetoclax Demonstrates Acceptable Safety in MCL
06/01/2021
Constantine Tam, MD, discusses results from a lead-in safety analysis of ibrutinib in combination with venetoclax for the treatment of patients with mantle cell lymphoma.
Constantine Tam, MD, discusses results from a lead-in safety analysis of ibrutinib in combination with venetoclax for the treatment of patients with mantle cell lymphoma.
Constantine Tam, MD, discusses...
06/01/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use